11 okt: Mermaid Technology - Positiv ordreindgang, opjustering og organis..
14 okt: 7 Cool Fund
13-10-2010 10:20:05

Ad hoc reports in accordance with section 15 of the German Securities Trading Act (WpHG) - Dräger raises 2010 guidance

Drägerwerk AG & Co. KGaA /

Ad hoc reports in accordance with section 15 of the German Securities Trading

Act (WpHG) - Dräger raises 2010 guidance

Processed and transmitted by Thomson Reuters.

The issuer is solely responsible for the content of this announcement.

For fiscal year 2010, Dräger is expecting an increase in net sales in the range of 10 percent (net sales 2009: EUR 1,911 billion). Net of currency effects, growth would then be in the mid single-digit range. After the company increased the forecast for the EBIT margin in June 2010 from originally 5 to 6 percent up to 7 to 8 percent, Dräger is now expecting an EBIT margin of 8 to 9 percent. As the cash settled option was replaced by an equity settled option on August 30, 2010, the impact from the Siemens cash option component has now been determined at EUR 11.8 million and is now included in this new guidance. The option component will not impact earnings in the future.

 

Now increased expectations for net sales and earnings are attributable to unexpectedly strong order intake, the unchanged positive development in the Americas and Asia-Pacific as well as favorable currency effects. The continuingly large share of high-margin equipment business in the medical division is a main contributor to higher profitability. The turnaround program is also having a highly positive effect and according to current estimates will contribute at least EUR 100 million to net earnings in 2010 against 2008. Originally the plan was to achieve a positive earnings effect of around EUR 70 million net in the current fiscal year and about EUR 100 million from 2011 on.

 

For 2011, Dräger intends to invest more into R&D, to implement projects more quickly and in particular to improve the marketing and sales organization. The company also assumes that one-time effects from the fiscal year 2010 will not recur. These include high levels of orders on hand from the previous year, strong order intake from large-scale projects, the sale of a deep-sea diving system for which an impairment charge was recorded for the full amount in 2009, the sale of software rights as well as the exceptionally advantageous product mix. External factors such as exchange rates are probably not going to benefit business in 2011 to the same degree. For 2011, Dräger is therefore not expecting to exceed the EBIT margin of the fiscal year 2010 amid slightly higher net sales. In the medium-term, the company is planning to grow stronger than the market and to achieve a sustained EBIT margin of at least 10 percent.

 

 

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55

23558 Lübeck, Deutschland

www.draeger.com

 

Investor Relations:

Vanina Herbst

Tel. +49 451 882-2685

vanina.herbst@draeger.com

 

Corporate Communications:

Burkard Dillig

Tel. +49 451 882-2185

burkard.dillig@draeger.com

 

 

Disclaimer

This ad-hoc release contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date and have been prepared to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors. They entail risks and uncertainties beyond the Company's control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this report. You will find all other financial dates on our website at www.draeger.com under Investor Center/Financial Calendar.

HUG#1451547

Press release (PDF)

--- End of Message ---

Drägerwerk AG & Co. KGaA

Moislinger Allee 53-55 Lübeck Germany

Listed: Freiverkehr in Börse Stuttgart,

Prime Standard in Frankfurter Wertpapierbörse,

Regulierter Markt in Frankfurter Wertpapierbörse,

Regulierter Markt in Bayerische Börse München,

Regulierter Markt in Börse Berlin,

Regulierter Markt in Hanseatische Wertpapierbörse zu Hamburg,

Regulierter Markt in Börse Düsseldorf,

Regulierter Markt in Niedersächsische Börse zu Hannover;

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the

information contained therein.

Source: Drägerwerk AG & Co. KGaA via Thomson Reuters ONE

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
19 mar
BAVA
Efter en fantastik uge vil jeg godt lige prøve at lave en evaluering af hvorfor jeg mener at der er ..
64
21 mar
PNDORA
  Jeg har flere gange analyseret Pandora, senest efter årsregnskabet. Den seneste tid har kursen vær..
60
21 mar
E:QEC
At jeg gør som jeg gør, og et lille indblik i hvilke gabs vi har liggende som sagtens kan fyldes på ..
24
23 mar
I:DAX
@marc55.   Lad mig give dig et velment råd.   Jeg er ikke en gammel sur mand (hverken gammel eller s..
19
21 mar
FING-B
Baronen84, jeg tager hatten af for dine RTX aktier, det er flot set :-)   Men at være hånlig overfor..
18
19 mar
I:DAX
Vorherre bevares!
18
24 mar
RTX
vi er  mange der er glade for at slippe for dig. TAK TIL EI.
17
22 mar
OMXC25
Det var så vigtigt vi skulle stemme. Jeg er glad for det blev et NEJ.   EU sagde vi ikke ville få en..
17
21 mar
VWS
idiot
15
23 mar
VWS
Dong Energy og Vestas får meldinger om off shore industrien, hvor de store olieselskaber øjnene muli..
14

Novo: EMA-udvalg anbefaler markedsføringstilladelse til Refixia - NY

24-03-2017 13:31:36
Udvalget for humanmedicinske lægemidler (CHMP) ved Det Europæiske Lægemiddelsagentur (EMA) har tildelt Novo Nordisks Refixia en positiv udtalelse og anbefaler en markedsføringstilladelse.Det skriver Novo Nordisk i en fondsbørsmeddelelse.CHMP anbefaler en markedsføringstilladelse til Refixia til unge og voksne med hæmofili B. Til grund for anbefalingen ligger resultater fra udviklingsprogrammet par..

Novo/Exane: Kursmålet skæres til 270 kr.

24-03-2017 10:17:22
Den franske storbank Exane BNP Paribas skærer kursmålet for aktien i Novo Nordisk til 270 kr. fra 295 kr. Anbefalingen er uændret "outperform", viser data fra Bloomberg.Novo-aktien falder fredag 0,4 pct., eller 1 kr., til 233,20 kr. Det dækker dog over en stigning, da aktien ikke længere handles inklusive retten til et udbytte på 4,60 kr./ritzau/FINANSJakob Dalskov +45 33 30 03 35 Ritzau Finans, E..

Aktier/tendens: Mulighed for mere gas til Mærsk i ventet rødt C20

24-03-2017 08:31:54
Det danske aktiemarked kan fredag blive præget af små udsving med en lille overvægt af negative fortegn.A.P. Møller-Mærsks B-aktie var uændret efter torsdagens handel og blev handlet til 11.500 kr. Aktien kan dog gå fra grå til grøn fredag, da der er potentielt gode nyheder til det danske konglomerat.Efter en Nordsø-aftale, der kan redde det ellers lukningstruede Tyra-felt, skriver Jyllands-Posten..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
26. marts 2017 00:46:15
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB1 - 2017-03-26 00:46:15 - 2017-03-26 00:46:15 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x